Principal Financial Group Inc Biotechnology

Principal Financial Group Inc

$176 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
MIRM Mirum Pharmaceuticals, Inc.	$2.65B	$1.6 Million 0.0% of portfolio	31,420	Q2 2025 New
VCYT Veracyte, Inc.	$2.53B	$1.53 Million 0.0% of portfolio	56,747	Q2 2025 Added 59.12%
ARGX Argenx Se	$45.4B	$1.38 Million 0.0% of portfolio	2,500	Q4 2024 New
RYTM Rhythm Pharmaceuticals, Inc.	$5.97B	$825,000 0.0% of portfolio	13,067	Q2 2025 Reduced 64.83%
XERS Xeris Biopharma Holdings, Inc.	$1.26B	$718,000 0.0% of portfolio	153,937	Q2 2025 Added 35.33%
AUPH Aurinia Pharmaceuticals Inc.	$1.72B	$640,000 0.0% of portfolio	75,666	Q2 2025 Added 645.04%
RPRX Royalty Pharma PLC	$16.1B	$587,000 0.0% of portfolio	16,304	Q2 2025 Reduced 14.05%
BPMC Blueprint Medicines Corp	$7.73B	$583,000 0.0% of portfolio	4,553	Q2 2025 Reduced 71.68%
MNKD Mannkind Corp	$1.43B	$536,000 0.0% of portfolio	143,444	Q2 2025 Reduced 28.44%
IONS Ionis Pharmaceuticals Inc	$10.5B	$314,000 0.0% of portfolio	7,951	Q2 2025 Reduced 23.89%
MDXG Mimedx Group, Inc.	$838M	$279,000 0.0% of portfolio	45,698	Q2 2025 Reduced 25.64%
PCVX Vaxcyte, Inc.	$2.65B	$279,000 0.0% of portfolio	8,612	Q2 2025 Reduced 98.17%
CRSP Crispr Therapeutics Ag	$4.77B	$275,000 0.0% of portfolio	5,667	Q2 2025 New
NUVL Nuvalent, Inc.	$4.22B	$233,000 0.0% of portfolio	3,056	Q2 2025 New
RNA Avidity Biosciences, Inc.	$3.63B	$230,000 0.0% of portfolio	8,116	Q2 2025 Reduced 10.52%
SRRK Scholar Rock Holding Corp	$1.45B	$203,000 0.0% of portfolio	5,758	Q2 2025 Reduced 8.63%
HRTX Heron Therapeutics, Inc.	$159M	$166,000 0.0% of portfolio	80,284	Q2 2025 Reduced 30.38%
CDXC Chroma Dex Corp.	$420M	$124,000 0.0% of portfolio	20,252	Q2 2025 New
RXRX Recursion Pharmaceuticals, Inc.	$1.02B	$122,000 0.0% of portfolio	24,150	Q2 2025 Added 20.33%
FOLD Amicus Therapeutics, Inc.	$2.5B	$113,000 0.0% of portfolio	19,806	Q2 2025 Reduced 15.43%
NVAX Novavax Inc	$659M	$66,000 0.0% of portfolio	10,580	Q2 2025 Reduced 11.19%
ARDX Ardelyx, Inc.	$810M	$65,000 0.0% of portfolio	16,783	Q2 2025 Reduced 88.75%
AKBA Akebia Therapeutics, Inc.	$570M	$61,000 0.0% of portfolio	16,949	Q2 2025 Added 18.38%
GERN Geron Corp	$468M	$60,000 0.0% of portfolio	43,178	Q2 2025 Reduced 3.74%
IBRX Immunity Bio, Inc.	$945M	$42,000 0.0% of portfolio	16,253	Q2 2025 Added 42.31%
ABUS Arbutus Biopharma Corp	$726M	$33,000 0.0% of portfolio	10,808	Q2 2025 Reduced 6.25%
NUVB Nuvation Bio Inc.	$1.12B	$33,000 0.0% of portfolio	17,141	Q2 2025 Added 45.78%
TSHA Taysha Gene Therapies, Inc.	$251M	$28,000 0.0% of portfolio	12,160	Q2 2025 Reduced 13.07%
GOSS Gossamer Bio, Inc.	$227M	$16,000 0.0% of portfolio	13,508	Q2 2025 New
ERAS Erasca, Inc.	$300M	$15,000 0.0% of portfolio	12,496	Q2 2025 Reduced 0.21%
PGEN Precigen, Inc.	$866M	$15,000 0.0% of portfolio	10,712	Q2 2025 New
ALLO Allogene Therapeutics, Inc.	$174M	$11,000 0.0% of portfolio	10,382	Q2 2025 New
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	55,446	Q2 2025 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.